SCHEMBL4677102

SCHEMBL4677102

O=C(O)C(O)=CC(=O)c1cocc1S(=O)(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
HTR6 P50406 6/20 0.36
GAA P10253 3/20 0.36
POLB P06746 1/20 0.36
GFER P55789 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MMP2 P08253 2/20 0.34
MMP3 P08254 2/20 0.34
MMP9 P14780 2/20 0.34
MMP8 P22894 2/20 0.34
MMP12 P39900 2/20 0.34
MMP13 P45452 2/20 0.34
MMP14 P50281 2/20 0.34
MMP16 P51512 2/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MMP1 P03956 1/20 0.34
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677099 1.00 NPSR1 (0.37) NPSR1TSHRHTTHTR6GAA
SCHEMBL4678047 0.88 MMP1 (0.38) GAAMMP2MMP3MMP9MMP12
SCHEMBL4678048 0.88 MMP1 (0.38) GAAMMP2MMP3MMP9MMP12
SCHEMBL4674107 0.88 ALDH1A1 (0.39) POLBALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4674114 0.88 ALDH1A1 (0.39) POLBALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4673980 0.78 NPSR1 (0.38) NPSR1TSHRHTTHTR6GAA
SCHEMBL4673976 0.78 NPSR1 (0.38) NPSR1TSHRHTTHTR6GAA
SCHEMBL4673350 0.77 ALDH1A1 (0.40) NPSR1TSHRHTTHTR6GAA
SCHEMBL4673354 0.77 ALDH1A1 (0.40) NPSR1TSHRHTTHTR6GAA
SCHEMBL4670850 0.74 HTR6 (0.36) NPSR1TSHRHTTHTR6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885TSHR 1614/4885HTT 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.